Single cell spatial analysis reveals inflammatory foci of immature neutrophil and CD8 T cells in COVID-19 lungs.
Journal article
Weeratunga P. et al, (2023), Nat commun, 14
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2.
Journal article
Higham HE. et al, (2023), Br j clin pharmacol
Optimising Psoriatic Arthritis Therapy with Immunological Methods to Increase Standard Evaluation: The protocol of an open-label multi-centre, parallel-group, two arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis.
Journal article
RICHARDS D., (2023), Bmj open
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Journal article
Gbinigie O. et al, (2023), Bmj open, 13
An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study
Journal article
Richards D. et al, (2022), Orphanet journal of rare diseases, 17
In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.
Journal article
Drennan PG. et al, (2022), Clin transl sci
In vivo human keyhole limpet haemocyanin challenge in early phase drug development: A systematic review
Journal article
Drennan P. et al, (2022), Clinical and translational science
Predictive validity in drug discovery: what it is, why it matters and how to improve it
Journal article
RICHARDS D., (2022), Nature reviews drug discovery
Corrigendum to 'Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes' [Surgery 171 (2021) 77-87].
Journal article
Shariq OA. et al, (2022), Surgery
COVID-19 therapeutics: challenges and directions for the future
Journal article
Robinson PC. et al, (2022), Proceedings of the national academy of sciences
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial.
Journal article
Dorward J. et al, (2022), Br j gen pract
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
Journal article
Wechalekar A. et al, (2022), Bmc cardiovasc disord, 22
Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Preprint
PRINCIPLE Trial Collaborative Group None. et al, (2022)
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
Journal article
Fisher BA. et al, (2021), The lancet respiratory medicine
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults.
Journal article
Veenith T. et al, (2021), Bmj open, 11
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Journal article
Yu L-M. et al, (2021), Lancet
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.
Journal article
Hinks TSC. et al, (2021), Lancet respir med